Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Align Tech (ALGN – Research Report), Immix Biopharma (IMMX – Research Report) and Beta Bionics, Inc. (BBNX – Research Report) with bullish sentiments.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Align Tech (ALGN)
HSBC analyst Sidharth Sahoo upgraded Align Tech to Buy today and set a price target of $200.00. The company’s shares closed last Friday at $187.60.
According to TipRanks.com, Sahoo is a 1-star analyst with an average return of
Currently, the analyst consensus on Align Tech is a Moderate Buy with an average price target of $196.89, representing a 10.7% upside. In a report issued on January 26, TipRanks – Google also upgraded the stock to Buy with a $188.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Immix Biopharma (IMMX)
Mizuho Securities analyst Graig Suvannavejh initiated coverage with a Buy rating on Immix Biopharma today and set a price target of $14.00. The company’s shares closed last Friday at $6.74.
According to TipRanks.com, Suvannavejh is a 5-star analyst with an average return of
Currently, the analyst consensus on Immix Biopharma is a Moderate Buy with an average price target of $12.00.
Beta Bionics, Inc. (BBNX)
Beta Bionics, Inc. received a Buy rating and a $24.00 price target from UBS analyst Danielle Antalffy on February 6. The company’s shares closed last Friday at $13.08, close to its 52-week low of $11.43.
According to TipRanks.com, Antalffy is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Beta Bionics, Inc. with a $27.50 average price target, implying a 104.2% upside from current levels. In a report issued on February 2, Piper Sandler also maintained a Buy rating on the stock with a $32.00 price target.
